- Women with recurrent/persistent platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers; platinum-resistant disease is defined as progression within < 6 months from completion of platinum based therapy.
- Patients must have histologically or cytologically confirmed ovarian cancer, peritoneal cancer or fallopian tube cancer and must have a histological diagnosis of high grade serous, grade 3 endometrioid or clear cell carcinoma.
- Patients with low grade serous, grade 1 or 2 endometrioid, mixed epithelial, undifferentiated carcinoma, mucinous or transitional cell carcinoma histologies are also eligible, provided that the patient has a known deleterious germline BRCA1 or BRCA2 mutation.
- At least two prior treatment regimens (including primary therapy) but up to 5 lines of systemic anticancer therapy. Hormonal therapy (such as tamoxifen, aromatase inhibitors) will not count as a previous treatment regimen.
- Prior use of bevacizumab in the upfront or recurrent setting is required.
- Prior use of PARP inhibitor is allowed.
- Prior use of immune checkpoint blockade is allowed.
- ECOG Performance Status of 0, 1, or 2.
- Primary platinum-refractory disease defined as progression during first-line platinum-based chemotherapy.
- Rising CA-125 only without RECIST 1.1 evaluable disease.
Please contact Legacy Oncology Research for additional study inclusion/exclusion information.